Adenosine analogue-oligo-arginine conjugates (ARCs) serve as high-affinity inhibitors and fluorescence probes of type I cGMP-dependent protein kinase (PKGIα)

Biochimica et Biophysica Acta - Proteins and Proteomics

Volumn 1804, Issue 9, 2010, Pages 1857-1868

  Lavogina, Darja ^a   Nickl, Christian K ^b   Enkvist, Erki ^a   Raidaru, Gerda ^a   Lust, Marje ^a   Vaasa, Angela ^a   Uri, Asko ^a   Dostmann, Wolfgang R ^b  

^a UNIVERSITY OF TARTU   (Estonia)

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

ARC; CAMP dependent protein kinase (PKA); CGMP dependent protein kinase (PKG); Fluorescence anisotropy; Pressure myography; Protein kinase inhibitor

Indexed keywords

ADENOSINE DERIVATIVE; ADENOSINE TRIPHOSPHATE DERIVATIVE; ARC 1028; ARC 1044; ARC 1067; ARC 1068; ARC 1069; ARC 1102; ARC 341; ARC 349; ARC 661; ARC 663; ARC 664; ARC 666; ARC 668; ARC 902; ARC 903; ARC 905; ARGININE DERIVATIVE; CYCLIC GMP DEPENDENT PROTEIN KINASE; CYCLIC GMP DEPENDENT PROTEIN KINASE INHIBITOR; CYCLIC NUCLEOTIDE DEPENDENT PROTEIN KINASE; DEXTRO ARGININE; DEXTRO LYSINE; OLIGOARGININE CONJUGATE; PROTEIN KINASE; STAUROSPORINE DERIVATIVE; UNCLASSIFIED DRUG; ADENOSINE; ARGININE; CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE 1; ENZYME INHIBITOR; FLUORESCENT DYE; PRKG1 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BRAIN ARTERY; CELL MEMBRANE; CEREBELLUM; COMPETITIVE INHIBITION; CONJUGATE; CONTROLLED STUDY; DRUG PROTEIN BINDING; ENZYME ACTIVE SITE; FLUORESCENCE; IC 50; IN VITRO STUDY; MOLECULAR PROBE; MOLECULAR SENSOR; MUSCLE TISSUE; NONHUMAN; PRIORITY JOURNAL; RAT; SMOOTH MUSCLE; STRUCTURE ACTIVITY RELATION; VASODILATATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; CYTOLOGY; DIAGNOSTIC USE; DRUG EFFECTS; HUMAN; METABOLISM; VASCULAR SMOOTH MUSCLE;

RATTUS;

ADENOSINE; ANIMALS; ARGININE; CEREBRAL ARTERIES; CYCLIC GMP; CYCLIC GMP-DEPENDENT PROTEIN KINASE TYPE I; CYCLIC GMP-DEPENDENT PROTEIN KINASES; ENZYME INHIBITORS; FLUORESCENCE; FLUORESCENT DYES; HUMANS; MUSCLE, SMOOTH, VASCULAR; RATS; VASODILATION;

EID: 77955093468     PISSN: 15709639     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbapap.2010.04.007     Document Type: Article

References (62)

1. Feil R., Lohmann S.M., de Jonge H., Walter U., Hofmann F. Cyclic GMP-dependent protein kinases and the cardiovascular system: insights from genetically modified mice. Circ. Res. 2003, 93:907-916.
2. Hofmann F., Bernhard D., Lukowski R., Weinmeister P. cGMP regulated protein kinases (cGK). cGMP: Generators, Effectors and Therapeutic Implications (Handbook of Experimental Pharmacology) 2009, 137-162. Springer, Berlin, Heidelberg. S.H.H.W. Harald, F.B. Hofmann, J.-P. Stasch (Eds.).
3. Makhlouf G.M., Murthy K.S. Signal transduction in gastrointestinal smooth muscle. Cell. Signal. 1997, 9:269-276.
4. Murthy K.S. Signaling for contraction and relaxation in smooth muscle of the gut. Annu. Rev. Physiol. 2006, 68:345-374.
5. Surks H.K. cGMP-dependent protein kinase I and smooth muscle relaxation: a tale of two isoforms. Circ. Res. 2007, 101:1078-1080.
6. Gambaryan S., Geiger J., Schwarz U.R., Butt E., Begonja A., Obergfell A., Walter U. Potent inhibition of human platelets by cGMP analogs independent of cGMP-dependent protein kinase. Blood 2004, 103:2593-2600.
7. Walter U., Gambaryan S. cGMP and cGMP-dependent protein kinase in platelets and blood cells. cGMP: Generators, Effectors and Therapeutic Implications (Handbook of Experimental Pharmacology) 2009, 533-548. Springer, Berlin, Heidelberg. S.H.H.W. Harald, F.B. Hofmann, J.-P. Stasch (Eds.).
8. Wood J.S., Yan X., Mendelow M., Corbin J.D., Francis S.H., Lawrence D.S. Precision substrate targeting of protein kinases. J. Biol. Chem. 1996, 271:174-179.
9. Kumar P., Van Patten S.M., Walsh D.A. Multiplicity of the beta form of the cAMP-dependent protein kinase inhibitor protein generated by post-translational modification and alternate translational initiation. J. Biol. Chem. 1997, 272:20011-20020.
10. Kumar P., Walsh D.A. A dual-specificity isoform of the protein kinase inhibitor PKI produced by alternate gene splicing. Biochem. J. 2002, 362:533-537.
11. Murthy K.S., Zhou H., Grider J.R., Makhlouf G.M. Inhibition of sustained smooth muscle contraction by PKA and PKG preferentially mediated by phosphorylation of RhoA. Am. J. Physiol. Gastrointest. Liver. Physiol. 2003, 284:G1006-G1016.
12. Butt E., Eigenthaler M., Genieser H.G. (Rp)-8-pCPT-cGMPS, a novel cGMP-dependent protein kinase inhibitor. Eur. J. Pharmacol. 1994, 269:265-268.
13. Butt E., Pdhler D., Genieser H.-G., Huggins J.P., Bucher B. Inhibition of cyclic GMP-dependent protein kinase-mediated effects by (Rp)-8-bromo-PET-cyclic GMPS. British J. Pharmacol. 1995, 116:3110-3116.
14. Hidaka H., Inagaki M., Kawamoto S., Sasaki Y. Isoquinolinesulfonamides, novel and potent inhibitors of cyclic nucleotide dependent protein kinase and protein kinase C. Biochemistry 1984, 23:5036-5041.
15. Chijiwa T., Mishima A., Hagiwara M., Sano M., Hayashi K., Inoue T., Naito K., Toshioka T., Hidaka H. Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H-89), of PC12D pheochromocytoma cells. J. Biol. Chem. 1990, 265:5267-5272.
16. Hidaka H., Kobayashi R. Pharmacology of protein kinase inhibitors. Annu. Rev. Pharmacol. Toxicol. 1992, 32:377-397.
17. Dostmann W.R.G., Nickl C., Thiel S., Tsigelny I., Frank R., Tegge W.J. Delineation of selective cyclic GMP-dependent protein kinase Iα substrate and inhibitor peptides based on combinatorial peptide libraries on paper. Pharmacol. Ther. 1999, 82:373-387.
18. Dostmann W.R.G., Taylor M.S., Nickl C.K., Brayden J.E., Frank R., Tegge W.J. Highly specific, membrane-permeant peptide blockers of cGMP-dependent protein kinase Iα inhibit NO-induced cerebral dilation. PNAS 2000, 97:14772-14777.
19. Nickl C.K., Raidas S.K., Zhao H., Sausbier M., Ruth P., Tegge W., Brayden J.E., Dostmann W.R. (d)-Amino acid analogues of DT-2 as highly selective and superior inhibitors of cGMP-dependent protein kinase Ialpha. Biochim. Biophys. Acta 2010, 1804:524-532.
20. Yan X., Lawrence D.S., Corbin J.D., Francis S.H. Distinguishing between closely related protein kinases: a variation on the bisubstrate inhibitor theme. J. Am. Chem. Soc. 1996, 118:6321-6322.
21. Yan X., Lawrence D.S., Corbin J.D., Francis S.H. Distinguishing between a mitogenic and two closely related nonmitogenic protein kinases. J. Am. Chem. Soc. 1996, 118:11684-11685.
22. Taskén K., Aandahl E.M. Localized effects of cAMP mediated by distinct routes of protein kinase A. Physiol. Rev. 2004, 84:137-167.
23. Dodge-Kafka K.L., Langeberg L., Scott J.D. Compartmentation of cyclic nucleotide signaling in the heart: the role of A-kinase anchoring proteins. Circ. Res. 2006, 98:993-1001.
24. Lafontan M., Moro C., Berlan M., Crampes F., Sengenes C., Galitzky J. Control of lipolysis by natriuretic peptides and cyclic GMP. Trends Endocrinol. Metab. 2008, 19:130-137.
25. Yan X.S., Ma J.H., Zhang P.H. Modulation of K(ATP) currents in rat ventricular myocytes by hypoxia and a redox reaction. Acta Pharmacol. Sin. 2009, 30:1399-1414.
26. St Hilaire R.C., Kadowitz P.J., Jeter J.R. Adenoviral transfer of vasoactive intestinal peptide (VIP) gene inhibits rat aortic and pulmonary artery smooth muscle cell proliferation. Peptides 2009, 30:2323-2329.
27. Nugent F.S., Niehaus J.L., Kauer J.A. PKG and PKA signaling in LTP at GABAergic synapses. Neuropsychopharmacology 2009, 34:1829-1842.
28. Kuroki H., Imai A., Nashida T., Shimomura H. Evidence for amylase release by cGMP via cAMP-dependent protein kinase in rat parotid acinar cells. Arch. Oral. Biol. 2007, 52:905-610.
29. Muzaffar S., Jeremy J.Y., Sparatore A., Del Soldato P., Angelini G.D., Shukla N. H2S-donating sildenafil (ACS6) inhibits superoxide formation and gp91phox expression in arterial endothelial cells: role of protein kinases A and G. Br. J. Pharmacol. 2008, 155:984-994.
30. Sánchez A., Villalba N., Martínez A.C., García-Sacristán A., Hernández M., Prieto D. Mechanisms of the relaxant effect of vardenafil in rat penile arteries. Eur. J. Pharmacol. 2008, 586:283-287.
31. Burgoyne J.R., Eaton P. Transnitrosylating nitric oxide species directly activate type I protein kinase A, providing a novel adenylate cyclase-independent cross-talk to beta-adrenergic-like signaling. J. Biol. Chem. 2009, 284:29260-29268.
32. Sisson J.H., Pavlik J.A., Wyatt T.A. Alcohol stimulates ciliary motility of isolated airway axonemes through a nitric oxide, cyclase, and cyclic nucleotide-dependent kinase mechanism. Alcohol. Clin. Exp. Res. 2009, 33:610-616.
33. Lavogina D., Enkvist E., Uri A. Bisubstrate inhibitors of protein kinases: from 815 principle to practical applications. ChemMedChem 2010, 5:23-34.
34. Lavogina D., Lust M., Viil I., König N., Raidaru G., Rogozina J., Enkvist E., Uri A., Bossemeyer D. Structural analysis of ARC-type inhibitor (ARC-1034) binding to protein kinase A catalytic subunit and rational design of bisubstrate analogue inhibitors of basophilic protein kinases. J. Med. Chem. 2009, 52:308-321.
35. Uri A., Lust M., Vaasa A., Lavogina D., Viht K., Enkvist E. Bisubstrate fluorescent probes and biosensors in binding assays for HTS of protein kinase inhibitors. Biochim. Biophys. Acta 2010, 1804:541-546.
36. Enkvist E., Lavogina D., Raidaru G., Vaasa A., Viil I., Lust M., Viht K., Uri A. Conjugation of adenosine and hexa-(d-arginine) leads to a nanomolar bisubstrate-analog inhibitor of basophilic protein kinases. J. Med. Chem. 2006, 49:7150-7159.
37. Enkvist E., Raidaru G., Vaasa A., Pehk T., Lavogina D., Uri A. Carbocyclic 3,-deoxyadenosine-based highly potent bisubstrate-analog inhibitor of basophilic protein kinases. Bioorg. Med. Chem. Lett. 2007, 17:5336-5339.
38. Enkvist E., Kriisa M., Roben M., Kadak G., Raidaru G., Uri A. Effect of the structure of adenosine mimic of bisubstrate-analog inhibitors on their activity towards basophilic protein kinases. Bioorg. Med. Chem. Lett. 2009, 19:6098-6101.
39. Vaasa A., Viil I., Enkvist E., Viht K., Raidaru G., Lavogina D., Uri A. High-affinity bisubstrate probe for fluorescence anisotropy binding/displacement assays with protein kinases PKA and ROCK. Anal. Biochem. 2009, 385:85-93.
40. Viht K., Padari K., Raidaru G., Subbi J., Tammiste I., Pooga M., Uri A. Liquid-phase synthesis of a pegylated adenosine-oligoarginine conjugate, cell-permeable inhibitor of cAMP-dependent protein kinase. Bioorg. Med. Chem. Lett. 2003, 13:3035-3039.
41. Räägel H., Lust M., Uri A., Pooga M. Adenosine-oligoarginine conjugate, a novel bisubstrate inhibitor, effectively dissociates the actin cytoskeleton. FEBS J. 2008, 275:3608-3624.
42. Honda A., Adams S.R., Sawyer C.L., Lev-Ram V., Tsien R.Y., Dostmann W.R.G. Spatiotemporal dynamics of guanosine 3, 5,-cyclic monophosphate revealed by a genetically encoded, fluorescent indicator. PNAS 2001, 98:5437-5442.
43. Heikal A.A., Hess S.T., Baird G.S., Tsien R.Y., Webb W.W. Molecular spectroscopy and dynamics of intrinsically fluorescent proteins: coral red (dsRed) and yellow (Citrine). PNAS 2000, 97:11996-12001.
44. Dostmann W.R.G., Tegge W., Frank R., Nickl C.K., Taylor M.S., Brayden J.E. Exploring the mechanisms of vascular smooth muscle tone with highly specific, membrane-permeable inhibitors of cyclic GMP-dependent protein kinase Iα. Pharmacol. Therap. 2002, 93:203-215.
45. Viht K., Vaasa A., Raidaru G., Enkvist E., Uri A. Fluorometric TLC assay for evaluation of protein kinase inhibitors. Anal. Biochem. 2005, 340:165-170.
46. Kuzmic P., Sideris S., Cregar L.M., Elrod K.C., Rice K.D., Janc J.W. High-throughput screening of enzyme inhibitors: automatic determination of tight-binding inhibition constants. Anal. Biochem. 2000, 281:62-67.
47. Nakase, Takeuchi T., Tanaka G., Futaki S. Methodological and cellular aspects that govern the internalization mechanisms of arginine-rich cell-penetrating peptides. Adv. Drug Deliv. Rev. 2008, 60:598-607.
48. Foley K.F., De Frutos S., Laskovski K.E., Tegge W., Dostmann W.R. Culture conditions influence uptake and intracellular localization of the membrane permeable cGMP-dependent protein kinase inhibitor DT-2. Front. Biosci. 2005, 10:1302-1312.
49. Puetz S., Lubomirov L.T., Pfitzer G. Regulation of smooth muscle contraction by small GTPases. Physiology 2009, 24:342-356.
50. Taylor M.S., Okwuchukwuasanya C., Nickl C.K., Tegge W., Brayden J.E., Dostmann W.R.G. Inhibition of cGMP-dependent protein kinase by the cell-permeable peptide DT-2 reveals a novel mechanism of vasoregulation. Mol. Pharmacol. 2004, 65:1111-1119.
51. Loog M., Uri A., Raidaru G., Järv J., Ek P. Adenosine-5,-carboxylic acid peptidyl derivatives as inhibitors of protein kinases. Bioorg. Med. Chem. Lett. 1999, 9:1447-1452.
52. Viht K., Schweinsberg S., Lust M., Vaasa A., Raidaru G., Lavogina D., Uri A., Herberg F.W. Surface-plasmon-resonance-based biosensor with immobilized bisubstrate analog inhibitor for the determination of affinities of ATP- and protein-competitive ligands of cAMP-dependent protein kinase. Anal. Biochem. 2007, 362:268-277.
53. Wyatt T.A., Pryzwansky K.B., Lincoln T.M. KT5823 activates human neutrophils and fails to inhibit cGMP-dependent protein kinase phosphorylation of vimentin. Res. Commun. Chem. Pathol. Pharmacol. 1991, 74:3-14.
54. Burkhardt M., Glazova M., Gambaryan S., Vollkommer T., Butt E., Bader B., Heermeieri K., Lincoln T.M., Walter U., Palmetshofer A. KT5823 inhibits cGMP-dependent protein kinase activity in vitro but not in intact human platelets and rat mesangial cells. J. Biol. Chem. 2000, 275:33536-33541.
55. Bain J., McLauchlan H., Elliott M., Cohen P. The specificities of protein kinase inhibitors: an update. Biochem. J. 2003, 371:199-204.
56. Pinkse M.W.H., Rijkers D.T.S., Dostmann W.R., Heck A.J.R. Mode of action of cGMP-dependent protein kinase-specific inhibitors probed by photoaffinity cross-linking mass spectrometry. J. Biol. Chem. 2009, 284:16354-16368.
57. Lundin P., Johansson H., Guterstam P., Holm T., Hansen M., Langel U., EL Andaloussi S. Distinct uptake routes of cell-penetrating peptide conjugates. Bioconjug. Chem. 2008, 19:2535-2542.
58. Jiao C.Y., Delaroche D., Burlina F., Alves I.D., Chassaing G., Sagan S. Translocation and endocytosis for cell-penetrating peptide internalization. J. Biol. Chem. 2009, 284:33957-33965.
59. Räägel H., Säälik P., Hansen M., Langel U., Pooga M. CPP-protein constructs induce a population of non-acidic vesicles during trafficking through endo-lysosomal pathway. J. Control. Release 2009, 139:108-117.
60. Watkins C.L., Brennan P., Fegan C., Takayama K., Nakase I., Futaki S., Jones A.T. Cellular uptake, distribution and cytotoxicity of the hydrophobic cell penetrating peptide sequence PFVYLI linked to the proapoptotic domain peptide PAD. J. Control. Release 2009, 140:237-244.
61. Watkins C.L., Schmaljohann D., Futaki S., Jones A.T. Low concentration thresholds of plasma membranes for rapid energy-independent translocation of a cell-penetrating peptide. Biochem. J. 2009, 420:179-189.
62. Rattan S., Phillips B.R., Maxwell P.J. RhoA/Rho-kinase: pathophysiologic and therapeutic implications in gastrointestinal smooth muscle tone and relaxation. Gastroenterology 2010, 138:13-18.